121 related articles for article (PubMed ID: 2473539)
21. [Effect of molsidomine on fibrinolytic activity: a double-blind, randomized study].
Darius H; Grodzinska L; Hafner G; Meyer J
Z Kardiol; 1991; 80 Suppl 5():47-50. PubMed ID: 1776335
[TBL] [Abstract][Full Text] [Related]
22. [Fibrinolytic activity and tissue plasminogen activator level in healthy individuals prior to and after a ten-minute venous stasis].
Kubicka A; Libura M; Sacha T; Swadźba J; Undas A; Wandzilak M
Pol Tyg Lek; 1993 Feb 1-8; 48(5-6):116-9. PubMed ID: 8361905
[TBL] [Abstract][Full Text] [Related]
23. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
24. Masking of fibrinolytic response to stimulation by an inhibitor of tissue-type plasminogen activator in plasma.
Brommer EJ; Verheijen JH; Chang GT; Rijken DC
Thromb Haemost; 1984 Oct; 52(2):154-6. PubMed ID: 6441302
[TBL] [Abstract][Full Text] [Related]
25. Release pattern of the vascular plasminogen activator and its inhibitor in human postvenous occlusion plasma as assessed by a spectrophotometric solid-phase fibrin-tPA activity assay.
Anglés-Cano E; Boutière B; Arnoux D; Masson C; Contant G; Benchimol P; Sampol J
Thromb Haemost; 1987 Oct; 58(3):843-9. PubMed ID: 3124285
[TBL] [Abstract][Full Text] [Related]
26. Altered fibrinolysis in DVT: influence of site of sampling.
Han P; Koay ES; Tsakok M; Aw TC; Wong LY; Pradhan M
Thromb Haemost; 1988 Aug; 60(1):50-3. PubMed ID: 3142091
[TBL] [Abstract][Full Text] [Related]
27. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
28. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
Bachmann F
Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901
[TBL] [Abstract][Full Text] [Related]
29. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor].
Köhler M; Miyashita C
Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347
[TBL] [Abstract][Full Text] [Related]
30. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
van Giezen JJ; Boon GI; Jansen JW; Bouma BN
Thromb Haemost; 1993 Apr; 69(4):381-6. PubMed ID: 8497851
[TBL] [Abstract][Full Text] [Related]
31. A dynamic test to investigate potential tissue plasminogen activator activity. Comparison of deamino-8-D-argininevasopressin with venous occlusion in normal subjects and patients.
Sultan Y; Harris A; Strauch G; Venot A; De Lauture D
J Lab Clin Med; 1988 Jun; 111(6):645-53. PubMed ID: 3131470
[TBL] [Abstract][Full Text] [Related]
32. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology.
Gris JC; Neveu S; Mares P; Biron C; Hedon B; Schved JF
J Lab Clin Med; 1993 Nov; 122(5):606-15. PubMed ID: 8228580
[TBL] [Abstract][Full Text] [Related]
33. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
34. Renal and hepatic handling of endogenous tissue-type plasminogen activator (t-PA) and its inhibitor in man.
Brommer EJ; Derkx FH; Schalekamp MA; Dooijewaard G; vd Klaauw MM
Thromb Haemost; 1988 Jun; 59(3):404-11. PubMed ID: 3142078
[TBL] [Abstract][Full Text] [Related]
35. Influence of metoprolol treatment on sympatho-adrenal activation of fibrinolysis.
Larsson PT; Wiman B; Olsson G; Angelin B; Hjemdahl P
Thromb Haemost; 1990 Jun; 63(3):482-7. PubMed ID: 2119530
[TBL] [Abstract][Full Text] [Related]
36. Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin.
Eriksson E; Wollter IM; Christenson B; Stigendal L; Risberg B
Thromb Haemost; 1988 Apr; 59(2):284-8. PubMed ID: 2838926
[TBL] [Abstract][Full Text] [Related]
37. An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion.
Speidl WS; Zeiner A; Nikfardjam M; Geppert A; Jordanova N; Niessner A; Zorn G; Maurer G; Schreiber W; Wojta J; Huber K
J Am Coll Cardiol; 2005 Jan; 45(1):30-4. PubMed ID: 15629369
[TBL] [Abstract][Full Text] [Related]
38. [Poor fibrinolytic response to venous occlusion: defect of endothelial cells or plasma interference?].
Stalder M; Hauert J; Bachmann F
Schweiz Med Wochenschr; 1983 Oct; 113(40):1462-4. PubMed ID: 6606226
[TBL] [Abstract][Full Text] [Related]
39. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
40. [Effect of thromboxane A2 synthetase inhibitor and prostacyclin analogue on arterial blood pressure, fibrinolysis and platelet function in patients with hypertension].
Nizankowski R; Krzanowski M; Musiał J; Szczeklik A
Pol Tyg Lek; 1991 Jan 7-14; 46(1-3):18-21. PubMed ID: 1726988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]